Relapsed or Refractory Multiple Myeloma Clinical Trials

14 recruiting

Frequently Asked Questions

Common questions about Relapsed or Refractory Multiple Myeloma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440 enrolled138 locationsNCT06615479
Recruiting
Phase 1

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
Phase 1

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC80 enrolled15 locationsNCT06604715
Recruiting
Phase 3

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 1

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.130 enrolled11 locationsNCT06375044
Recruiting
Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Relapsed or Refractory Multiple Myeloma
Genentech, Inc.120 enrolled14 locationsNCT05927571
Recruiting
Phase 3

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.228 enrolled1 locationNCT07138209
Recruiting
Phase 1Phase 2

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.166 enrolled10 locationsNCT07116616
Recruiting
Phase 1

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma
Excyte Biopharma Ltd70 enrolled12 locationsNCT06574568
Recruiting
Phase 1

Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma
O&D BioTech Group CO., Limited18 enrolled1 locationNCT07369895
Recruiting
Phase 2

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD90 enrolled1 locationNCT07312188
Recruiting
Phase 1

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital18 enrolled1 locationNCT07003555
Recruiting
Phase 1

Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital18 enrolled1 locationNCT07003568
Recruiting
Phase 2

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.160 enrolled1 locationNCT07018050
Recruiting
Phase 1Phase 2

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma
Zhejiang ACEA Pharmaceutical Co. Ltd.84 enrolled4 locationsNCT05565807
Recruiting
Phase 1

YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT05913804
Recruiting
Not Applicable

Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

Lymphoblastic LeukemiaRelapsed or Refractory Multiple Myeloma (RRMM)
Anhui Provincial Hospital18 enrolled1 locationNCT06961669
Recruiting
Phase 1Phase 2

Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma (RRMM)
Chengdu Zenitar Biomedical Technology Co., Ltd144 enrolled1 locationNCT06484829
Recruiting
Phase 1Phase 2

A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

Relapsed or Refractory Multiple Myeloma
Beijing Mabworks Biotech Co., Ltd.154 enrolled1 locationNCT06232096